Efficacy and Safety Study of Wearable Cyborg HAL (Hybrid Assistive Limb) in Hemiplegic Patients With Acute Stroke (EARLY GAIT Study): Protocols for a Randomized Controlled Trial

Frontiers in Neuroscience

Hideki Kadone¹  Kazushi Maruo²  Hiroki Watanabe³  Hideo Tsurushima³  Yoshiro Ito³  Masayuki Sato³  Aiki Marushima³  Eiichi Ishikawa³  Shigeki Kubota⁴  Yasushi Hada⁵  Yukiyo Shimizu⁵  Tenyu Hino⁶  Yuji Matsumaru⁶  Mikito Hayakawa⁶ 

[1] Center for Cybernics Research, University of Tsukuba, Tsukuba, Japan;Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan;Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan;Department of Orthopaedic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan;Department of Rehabilitation Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan;Division of Stroke Prevention and Treatment, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan;

关键词: wearable cyborg;    Hybrid Assistive Limb;    acute stroke;    independent walking;    functional ambulation category;    randomized controlled trial;   

DOI  :  10.3389/fnins.2021.666562

来源: DOAJ

【 摘 要 】

We hypothesized that gait treatment with a wearable cyborg Hybrid Assistive Limb (HAL) would improve the walking ability of patients with hemiparesis after stroke. This study aims to evaluate the efficacy and safety of gait treatment using HAL versus conventional gait training (CGT) in hemiplegic patients with acute stroke and establish a protocol for doctor-initiated clinical trials for acute stroke. We will enroll patients with acute stroke at the University of Tsukuba Hospital. This study is a single-center, randomized, parallel-group, controlled trial (HAL group, n = 20; control group, n = 20) that will include three phases: (1) pre-observation phase (patient enrollment, baseline assessment, and randomization); (2) treatment phase (nine sessions, twice or thrice per week over 3−4 weeks; the HAL and control groups will perform gait treatment using HAL or CGT, respectively, and finally (3) post-treatment evaluation phase. The Functional Ambulation Category score will be the primary outcome measure, and the following secondary outcome measures will be assessed: Mini-Mental State Examination, Brunnstrom recovery stage of lower limbs, Fugl–Meyer assessment of lower limbs, 6-min walking distance, comfortable gait speed, step length, cadence, Barthel Index, Functional Independence Measure, gait posture, motion analysis (muscle activity), amount of activity (evaluated using an activity meter), stroke-specific QOL, and modified Rankin Scale score. The baseline assessment, post-treatment evaluation, and follow-up assessment will evaluate the overall outcome measures; for other evaluations, physical function evaluation centered on walking will be performed exclusively, excluding ADL and QOL scores. This study is a randomized controlled trial that aims to clarify the efficacy and safety of gait treatment using HAL compared with CGT in hemiplegic patients with acute stroke. In addition, we aim to establish a protocol for doctor-initiated clinical trials for acute stroke based on the study results. If our results demonstrate the effectiveness of the proposed treatment regarding outcomes of patients with hemiplegic acute stroke, this study will promote the treatment of these patients using the HAL system as an effective tool in future stroke rehabilitation programs. The study protocol was registered with the Japan Registry of Clinical Trials on October 14, 2020 (jRCTs032200151).

【 授权许可】

Unknown